NCT07207707phase 1recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Kumquat Biosciences Inc.

ClinicalTrials.gov

Enrollment · estimated

Countries · 13 sites

2026-09

Primary completion

3 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Biomarker requirement language

Pathologically confirmed, locally advanced or metastatic PDAC, CRC, or NSCLC with a KRAS G12D mutation

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
53/100
Opportunity
New phase 1 trial NCT07207707 posted by Kumquat Biosciences Inc.: "A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies".
ClinicalTrials.gov record updated 111 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Pathologically confirmed, locally advanced or metastatic PDAC, CRC, or NSCLC with a KRAS G12D mutation
* Progressed on, or intolerant to at least one prior line of systemic standard of care therapy
* Measurable disease according to RECIST v1.1
* Adequate organ function

Exclusion Criteria:

* Previous treatment with a KRAS G12D inhibitor or pan-RAS inhibitor
* History of intestinal disease, uncontrolled inflammatory bowel disease (e.g., Crohn's disease, Ulcerative Colitis), major esophageal or gastric surgery, or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study intervention or result in inability to swallow oral medications
* Poorly controlled ascites and/or pleural effusion
* Requires treatment with a strong and/or moderate CYP3A inhibitor or inducer
* Requires treatment with a proton-pump inhibitor